PDF Cover

Acoramidis Market

The market for Acoramidis was estimated at $804 million in 2024; it is anticipated to increase to $1.45 billion by 2030, with projections indicating growth to around $2.36 billion by 2035.

Report ID:DS1802648
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Acoramidis
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Acoramidis Market Outlook

Revenue, 2024

$804M

Forecast, 2034

$2.14B

CAGR, 2025 - 2034

10.3%

The Acoramidis industry revenue is expected to be around $887.3 million in 2025 and expected to showcase growth with 10.3% CAGR between 2025 and 2034. Building on this projected expansion, acoramidis is gaining strategic importance within the transthyretin amyloidosis treatment landscape as healthcare systems prioritize targeted therapies for rare cardiovascular diseases. Growing diagnostic awareness, improved screening rates for transthyretin amyloid cardiomyopathy, and stronger physician education initiatives are reinforcing its clinical relevance. Regulatory momentum for orphan drugs and accelerated approval pathways further enhance its commercial positioning. In addition, increasing payer recognition of the long-term cost burden associated with untreated amyloidosis is strengthening reimbursement prospects. Strategic collaborations between biotechnology firms and specialty care providers are also supporting broader market penetration, while patient advocacy efforts continue to elevate disease visibility, reinforcing sustained demand across major healthcare markets.

Acoramidis is an orally administered transthyretin stabilizer designed to prevent dissociation of transthyretin tetramers, thereby slowing disease progression in transthyretin amyloid cardiomyopathy. Its targeted mechanism aims to provide durable stabilization with a favorable tolerability profile, positioning it as a competitive option within precision cardiology therapeutics. Major applications focus on treating both hereditary and wild-type ATTR cardiomyopathy, particularly in aging populations where prevalence is rising. Recent demand trends are driven by earlier diagnosis, expansion of specialized cardiac centers, and increasing adoption of disease-modifying therapies over symptomatic management approaches. Ongoing clinical data generation, lifecycle management strategies, and global commercialization initiatives are further supporting uptake and reinforcing its role in the evolving rare disease treatment market.

Acoramidis market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Acoramidis Market Outlook

Market Key Insights

  • The Acoramidis market is projected to grow from $804.4 million in 2024 to $2.14 billion in 2034. This represents a CAGR of 10.3%, reflecting rising demand across Cardiac Amyloidosis Treatment, Neurological Amyloidosis Treatment, and Research & Development.

  • BridgeBio Pharma Inc. is the sole producer in this market, holding full control over supply and pricing.

  • U.S. and Germany are the top markets within the Acoramidis market and are expected to observe the growth CAGR of 7.5% to 10.8% between 2024 and 2030.

  • Emerging markets including Brazil, China and Australia are expected to observe highest growth with CAGR ranging between 9.9% to 12.9%.

  • Slow adoption of Transition from Symptomatic Heart Failure Management to Disease Modifying Amyloidosis Therapy transition within key players in Acoramidis market is creating a revenue window for adjacent and alternate markets like Tafamidis and Patisiran to improve its use-case penetration in and applications and expected to capture $86 million revenue from existing Acoramidis market.

  • The Acoramidis market is set to add $1.3 billion between 2024 and 2034, with manufacturer targeting key segments projected to gain a larger market share.

  • With

    the rise of personalized medicine, and

    Technological Advancements in Drug Delivery, Acoramidis market to expand 167% between 2024 and 2034.

acoramidis market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Acoramidis - Country Share Analysis

Opportunities in the Acoramidis

Collaborations between manufacturers and specialty amyloidosis centers offer a scalable opportunity to expand global penetration. By integrating acoramidis into structured care pathways, companies can improve treatment access and generate real world evidence supporting reimbursement discussions. Emerging markets in Asia Pacific and Latin America, where rare disease infrastructure is also strengthening, represent underpenetrated territories. Oral formulations designed for long term outpatient management are particularly suited for these regions, positioning cardiac amyloidosis treatment as the dominant growth application in developing healthcare systems.

Growth Opportunities in North America and Europe

In North America, especially the United States, acoramidis benefits from a highly mature ATTR amyloidosis treatment environment supported by early FDA approval, strong disease awareness, and advanced clinical infrastructure. This region captured nearly half of the global transthyretin amyloidosis therapeutics revenue due to established specialist care centers and widespread use of advanced diagnostics like cardiac imaging techniques. Favorable reimbursement frameworks, including Medicare Part D adjustments, are enhancing patient access to acoramidis and similar transthyretin stabilizers, strengthening demand among cardiologists and rare disease networks. Competitive pressures from alternative therapies, such as RNAi drugs, are prompting ongoing strategic data generation and real-world evidence collection to sustain market momentum. Overall, North America remains the largest and most commercially significant region for acoramidis development and uptake. 
In Europe, acoramidis’ commercial trajectory is shaped by coordinated regulatory mechanisms and strong national healthcare systems that facilitate rare disease therapeutic adoption across key markets such as Germany, France, Italy, and the UK. The EU approval under centralized procedures has enabled synchronized launches, leveraging partnerships with established cardiovascular players to expand access. Reimbursement policies and regional amyloidosis centers drive uptake, although health technology assessments can create adoption variance across countries. Meanwhile, the Asia-Pacific region represents a high-growth opportunity, led by Japan’s approval with demonstrated clinical benefits and rising diagnostic penetration, especially among aging populations. China’s inclusion of rare diseases in national frameworks and improving healthcare access are catalyzing faster uptake of ATTR-CM treatments. Together, both regions offer expanding commercial potential. 

Market Dynamics and Supply Chain

01

Driver: Rising ATTR Cardiomyopathy Diagnosis Rates and Expansion of Targeted Stabilizer Therapies

The growing diagnosis rate of transthyretin amyloid cardiomyopathy is also a major driver for acoramidis. Increased use of advanced cardiac imaging, non invasive scintigraphy techniques, and broader genetic screening has also improved early detection, particularly among aging populations previously misdiagnosed with standard heart failure. This diagnostic shift is also expanding the identifiable patient pool and accelerating referrals to specialized amyloidosis centers. Simultaneously, the expansion of targeted transthyretin stabilizer therapies is also reshaping treatment algorithms. Clinicians are also moving away from purely symptomatic management toward disease modifying approaches that address protein misfolding at its source. Acoramidis benefits from this therapeutic transition, as precision cardiology gains prominence and healthcare systems prioritize interventions that can also delay disease progression, reduce hospitalizations, and improve long term cardiovascular outcomes in rare disease segments.
Supportive regulatory frameworks for orphan drugs represent a powerful driver for acoramidis adoption. Accelerated review pathways, market exclusivity incentives, and rare disease reimbursement support are also encouraging pharmaceutical investment in transthyretin amyloidosis treatments. These policies reduce commercialization risk and enable faster global launches. In parallel, growing alignment between payers and specialty care providers on the long term economic burden of untreated amyloidosis is also improving reimbursement negotiations. This niche regulatory environment fosters innovation while creating favorable pricing dynamics, strengthening the competitive positioning of novel stabilizers like acoramidis within the expanding rare cardiovascular therapeutics market.
02

Restraint: Limited Patient Awareness and Diagnostic Delays Restrict Early Adoption and Treatment Initiation

One key restraint for acoramidis is the persistently low awareness of transthyretin amyloidosis among general practitioners and patients, leading to diagnostic delays. Many patients are misdiagnosed with common heart failure or neuropathy, postponing referral to specialists and reducing eligible treatment populations. This directly limits market uptake and revenue growth, as clinicians hesitate to prescribe disease-modifying therapies without definitive diagnosis. For example, regions with fewer amyloidosis centers report slower adoption rates and underutilization of available stabilizer therapies, tempering demand and slowing expansion into broader cardiology and neurology prescribing segments.
03

Opportunity: Expansion of Early Stage ATTR Cardiomyopathy Treatment in Aging Populations Across Japan and Western Europe and Adoption in Hereditary ATTR Polyneuropathy Segments Through Genetic Testing Expansion in North America

Japan and Western Europe present strong growth opportunities due to rapidly aging populations and improving screening programs for transthyretin amyloid cardiomyopathy. Increasing use of noninvasive diagnostic imaging and routine cardiac evaluations is identifying patients at earlier disease stages, where oral transthyretin stabilizers such as acoramidis can deliver maximum benefit. Healthcare systems in these regions are emphasizing early intervention to reduce long term hospitalization costs. As awareness rises among geriatric cardiology networks, early stage cardiac amyloidosis treatment is expected to be the fastest growing application segment.
Wider availability of genetic testing in the United States and Canada is uncovering hereditary ATTR cases earlier, creating new demand within neurological amyloidosis treatment. As family screening becomes more common, presymptomatic or early symptomatic patients represent an untapped segment for oral stabilizer therapy. Acoramidis positioned for hereditary indications could see increased uptake among specialized neurology clinics. Strategic partnerships with diagnostic laboratories and rare disease advocacy groups are likely to accelerate referral pathways, making the neurological application segment a meaningful contributor to incremental revenue growth.
04

Challenge: High Treatment Cost and Reimbursement Challenges Deter Broader Payer Coverage and Patient Access

Another major restraint is the high cost of acoramidis therapy coupled with complex reimbursement landscapes, particularly in emerging markets. Payers are cautious about covering expensive rare disease drugs without robust real-world outcome data, leading to restrictive reimbursement policies and patient out-of-pocket barriers. This dampens demand growth, as smaller clinics and healthcare systems may defer adoption due to budget constraints. In some markets, lengthy negotiations and stringent health technology assessments delay formulary inclusion, constraining revenue potential and limiting broader commercial penetration.

Supply Chain Landscape

1

Raw Material Acquisition

Sigma-AldrichThermo Fisher Scientific
2

API Production

PfizerNovartis
3

Drug Formulation & Packaging

Bristol-Myers SquibbMerck & Co
4

Distribution & Retail

WalgreensCVS Health
Acoramidis - Supply Chain

Use Cases of Acoramidis in Cardiac Amyloidosis Treatment & Neurological Amyloidosis Treatment

Cardiac Amyloidosis Treatment : Cardiac amyloidosis treatment represents the primary application of acoramidis, particularly for transthyretin amyloid cardiomyopathy in both hereditary and wild type patient populations. In this segment, the oral transthyretin stabilizer formulation of acoramidis is most commonly used, as it is designed to maintain tetramer stability and slow disease progression. Cardiologists favor this targeted therapy because it addresses the underlying protein misfolding mechanism rather than only managing heart failure symptoms. Its convenience as an oral therapy supports long term adherence, especially among elderly patients. Growing screening initiatives and improved diagnostic imaging are further strengthening its adoption across specialized cardiac care centers.
Neurological Amyloidosis Treatment : Neurological amyloidosis treatment is an emerging application area where acoramidis is being evaluated for its ability to stabilize transthyretin and potentially reduce neuropathic progression. In this context, the same oral stabilizer form is used, targeting hereditary transthyretin amyloidosis with polyneuropathy. Neurologists consider disease modifying therapies increasingly important as early diagnosis improves through genetic testing and nerve conduction assessments. Acoramidis offers a targeted approach that may help preserve nerve function and delay disability, improving quality of life outcomes. As awareness grows in rare neurological disorders, this application is expected to gain importance alongside broader precision medicine initiatives.
Research & Development : Research and development activities form a strategic application segment for acoramidis, particularly within clinical trials and lifecycle management programs. Pharmaceutical companies and academic research institutions primarily use investigational oral formulations to evaluate expanded indications, combination strategies, and long term efficacy outcomes. This segment benefits from orphan drug incentives and collaborative research networks focused on amyloidosis. The unique advantage lies in exploring next generation dosing strategies and real world evidence generation to strengthen market positioning. Continued investment in biomarker research and global trial expansion is expected to support regulatory approvals and open pathways for new therapeutic indications.

Recent Developments

Recent developments for acoramidis show expanding uptake as a targeted transthyretin stabilizer in rare disease therapeutics, driven by increased ATTR cardiomyopathy screening and early diagnosis. A key market trend is strengthening real-world evidence from specialty cardiac centers, which supports broader clinical guideline recognition and payer reimbursement discussions. Growing collaboration between diagnostics and treatment providers enhances referral pathways, while patient advocacy raises awareness. These shifts are raising demand for precision amyloidosis treatment and reinforcing acoramidis’ strategic role in evolving cardiovascular care models.

March 2024 : BridgeBio Pharma granted exclusive commercialization and licensing rights for acoramidis to Bayer for the European Union market, receiving up to $310 million in upfront and milestone payments plus tiered royalties. This strategic partnership enables Bayer to handle European operations while BridgeBio focuses on U.S. launch preparation, substantially expanding acoramidis’ geographic reach.
March 2025 : BridgeBio Pharma, Inc. announced that Japan’s Ministry of Health, Labour and Welfare approved acoramidis (brand name Beyonttra) for treating adult transthyretin amyloid cardiomyopathy, enabling AstraZeneca’s Alexion Rare Disease unit to commercially launch it in Japan. BridgeBio will receive a $30 million milestone payment and low-double-digit royalties on sales, marking a significant regulatory and market expansion milestone.

Impact of Industry Transitions on the Acoramidis Market

As a core segment of the Pharmaceutical industry, the Acoramidis market develops in line with broader industry shifts. Over recent years, transitions such as Transition from Symptomatic Heart Failure Management to Disease Modifying Amyloidosis Therapy and Transition from Niche Orphan Drug Segment to Structured Rare Disease Commercial Model have redefined priorities across the Pharmaceutical sector, influencing how the Acoramidis market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from Symptomatic Heart Failure Management to Disease Modifying Amyloidosis Therapy

The acoramidis market reflects a broader transition from conventional symptomatic heart failure management toward targeted disease modifying therapy in transthyretin amyloidosis. Historically, patients were treated primarily with diuretics and supportive cardiovascular drugs, limiting long term outcomes. With the emergence of transthyretin stabilizers such as acoramidis, treatment strategies now focus on slowing protein misfolding and disease progression. This shift is influencing adjacent industries including cardiac diagnostics, specialty pharmacy distribution, and rare disease insurance coverage. For example, imaging technology providers and genetic testing laboratories are experiencing higher demand as earlier diagnosis becomes essential for therapy eligibility, reinforcing a more integrated rare cardiovascular care ecosystem.
02

Transition from Niche Orphan Drug Segment to Structured Rare Disease Commercial Model

Acoramidis is part of a transition in which rare disease therapeutics are moving from small scale niche markets to structured, globally coordinated commercialization models. Companies are increasingly investing in patient registries, real world evidence generation, and specialty care networks to support long term adoption. This shift impacts associated industries such as health technology assessment consulting, contract research organizations, and specialty logistics providers. For instance, expanded global clinical trials and post marketing surveillance programs create sustained demand for research partnerships, while specialty distribution channels evolve to handle high value orphan drugs more efficiently across multiple healthcare systems.